Learner ObjectivesUpon completion of this activity, you should be able to:
FacultyAmrut Ambardekar, MD, FACC University of Colorado Health DisclosureNothing to disclose. Richard Kar-Hang Cheng, MD, FACC University of Washington Medical CenterDisclosureNothing to disclose. Jan Griffin, MD, FACC Medical University of South CarolinaDisclosure Fees/Honoraria: AstraZeneca Pharmaceuticals, Bridgebio, Pfizer Inc Research/Research Grants: Pfizer Other: Bridgebio, ScrippsPlanning CommitteeMichelle Maya Kittleson, MD, FACC (Chair)California Heart CenterDisclosureNothing to disclose.Target AudienceThis course is intended for general cardiologists and other members of the CV team who see patients with amyloid or possible amyloid.Important Dates Date of Release: June 30, 2025Term of Approval/Date of Expiration: June 30, 2026Grant AcknowledgementEducational grant support for this activity provided by: Alnylam Pharmaceuticals Inc., BridgeBio Pharma Inc., and Pfizer